NICHOLAS CAMPBELL: Open Payments
NPI 1285229070 · BERKLEY, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$461 in 23 payments from 11 companies in 2025. Trend: 2023 $712 · 2024 $608 · 2025 $461
Food & beverage: $461
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 5 | $96 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $94 |
| PFIZER INC. | 3 | $49 |
| Actelion Pharmaceuticals US, Inc. | 1 | $41 |
| Amgen Inc. | 2 | $38 |
| AstraZeneca Pharmaceuticals LP | 2 | $32 |
| Novo Nordisk Inc | 1 | $25 |
| E.R. Squibb & Sons, L.L.C. | 1 | $24 |
| Merck Sharp & Dohme LLC | 1 | $23 |
| ABIOMED | 1 | $22 |
Products named: LEQVIO, JARDIANCE, ELIQUIS, OPSUMIT, REPATHA, FARXIGA, Wegovy, VERQUVO.
Industry payments across MI — which companies pay providers there.
